Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
about
The protease inhibitor bikunin, a novel anti-metastatic agentCrystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptideUrokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesProstate cancer relevant antigens and enzymes for targeted drug deliveryStructure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPYPET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectivesThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingCollisional activation by MALDI tandem time-of-flight mass spectrometry induces intramolecular migration of amide hydrogens in protonated peptidesIsothiocyanate-Functionalized Bifunctional Chelates and fac-[M(I)(CO)3](+) (M = Re, (99m)Tc) Complexes for Targeting uPAR in Prostate CancerMapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallographyMapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.Phage display in molecular imaging and diagnosis of cancer.Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migrationPhage display and molecular imaging: expanding fields of vision in living subjects.Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR)Antimetastatic potential of PAI-1-specific RNA aptamers.First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.Extracellular proteolysis in transgenic mouse models of breast cancerPeptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105Stroma targeting nuclear imaging and radiopharmaceuticals.First-in-human uPAR PET: Imaging of Cancer Aggressiveness.Structural basis of interaction between urokinase-type plasminogen activator and its receptorPreclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeysA flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroUrokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapyuPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.Urokinase plasminogen activator system as a potential target for cancer therapy.uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.GPI transamidase and GPI anchored proteins: oncogenes and biomarkers for cancer.A novel peptide blocking cancer cell invasion by structure-based drug design.Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
P2860
Q24305858-0F06F1BD-6F1C-4AA2-A0B2-8AAEFF537CB5Q24529128-33D8FBE8-4AAF-45F8-A414-4B5AF8CE345FQ26865306-2323FEF1-7C92-4329-97DA-491A72DC8386Q26995399-0840824F-A0BC-4CC8-8019-C3349E5F4238Q27013843-34C6CAA5-29FE-49A8-B72D-118445B79CD5Q27659603-3C920E6C-9259-4A7F-B147-84905519A62DQ28078479-C846FE75-2C4E-472C-9EF0-E48CD3BB45FDQ28257803-C039B05B-DEB9-4BC3-B239-83B8BA29D88DQ28269441-394D3A74-CB70-4096-8C5C-7E71B945C40EQ28821362-43B444B0-AE2D-4FEF-BD80-BD7A4E4D33E2Q30380709-689ADB1C-7C14-4DA2-A0C0-341D16F4BBD2Q33278178-EA0695BE-5244-47F2-9A5C-601B96868161Q33417714-801A7DF8-5A60-4029-BD8A-4799A59601EBQ33532734-7B49E931-3704-4B06-98A8-8E1B425AEFCBQ33587120-1B3A4447-353F-44A0-8C0D-68E7B84ABE0FQ33849788-F9540669-D871-4D4A-9E4F-A80678E91FBCQ33912826-455D550F-EAE0-4AE1-8708-24528356AD5CQ34167905-27822F48-C95F-4F34-9D63-E886FEBD595EQ34442512-B171705C-2880-4CE6-A3BF-385213301AD5Q34766934-EF9B8A2B-47EF-46D4-8E2F-99A1A701EEDEQ34992753-2671FAC3-520F-4110-8C3B-59F7621E0823Q35312973-C8F523FF-89D6-4BC7-922B-6E01164CA16AQ35677095-D103FC72-D19B-4669-A610-82D922CA40C5Q35909379-23A6F8C1-A46B-4A5D-BE7A-409EF4437768Q35999606-58AA1695-12AC-4B02-B39C-20F88505ADF5Q36191589-E7A7B047-9A64-4941-8B04-F269454CCCEBQ36237711-0A93DF7C-6036-4625-A8A3-E0A61FB7DE93Q36240694-8BD165DE-3369-4E13-8385-48D9BB04FE6AQ36298409-57F9E69E-A003-4E72-AD14-366DF4CCEAA5Q36791190-0A09703C-4C9C-4A5E-A375-A51CAA9231F6Q36997627-22196FE1-54BF-4991-B2FE-9FD9066A12B4Q37435242-7946A66F-9E33-49C6-8737-845D43B88FF9Q37630593-5F930CA3-2784-4442-9193-5CE8350051DBQ37716562-D49BEB4B-B2FE-4DCF-AAA0-826C8EC45C31Q37783622-DAF8E169-8BA9-47FF-8AF7-AC10EDF8C6F1Q37895294-26605A60-1410-45B4-BF02-02160A8EAF4EQ38120755-4C63F014-1376-4989-B5D4-C88C16999E82Q38131553-1000640C-F99D-4E2B-91A1-5852FDEE1B13Q38694644-6DFE1C22-7CE1-4365-A72E-2726F7F00AE8Q38711633-2389524E-5D78-4CF6-AE40-8A2C05627137
P2860
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Peptide-derived antagonists of ...... on cancer cell intravasation.
@en
type
label
Peptide-derived antagonists of ...... on cancer cell intravasation.
@en
prefLabel
Peptide-derived antagonists of ...... on cancer cell intravasation.
@en
P2093
P356
P1433
P1476
Peptide-derived antagonists of ...... on cancer cell intravasation.
@en
P2093
C Holst-Hansen
H Gårdsvoll
K Kovalski
L Ossowski
S Østergaard
P304
12157-12168
P356
10.1021/BI010662G
P407
P577
2001-10-01T00:00:00Z